Search results for: 'vital diagnostics'

Precision diagnosis in today's healthcare is pivotal, tailoring treatment to individual patients based on genetic, molecular, and environmental factors. This targeted approach enhances accuracy, enables early detection and targeted treatment, minimizes trial-and-error treatment, and optimizes therapeutic outcomes. By leveraging advanced technol...

This study provides data for the Western European in vitro diagnostics (IVD) market. Haematology, haemostasis, urinalysis, microbiology, clinical chemistry, point-of-care testing, molecular diagnostics, tissue diagnostics, self-monitoring blood glucose and immunochemistry are the segments within this market. Market revenues have been included in th...

17 Jul 2017  |  North America  |  Market Research

US Oncology Diagnostics Market, Forecast to 2021

Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection

Infographics

×

Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolida...

Despite global economic and industry challenges, in vitro diagnostics (IVD) markets are growing robustly at double the rate of the global pharmaceutical industry. The global IVD market size was $47.30 billion in 2013; it is expected to reach $62.63 billion in 2017, at a compound annual growth rate of 7.3%. Because of stagnating mature markets, comp...

This research study provides an analysis of the in vitro diagnostics (IVD) market in India. It quantifies market size, provides insight into the burden of diseases in India, and examines market dynamics from 2007 to 2017. It provides an in-depth analysis of the competitive environment by highlighting the competitive structure, diagnostic service la...

Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits that can rapidly rule MI in or out. Both factors serve as signif...

This research service analyzes the IVD market in Australia strategically by evaluating the various forces that are currently influencing this market. It analyzes the revenue potential for the key segments in this market, namely clinical chemistry, immunoassay, hematology, coagulation, microbiology, molecular diagnostics, self-monitoring of blood gl...

The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher do...

The unmet need to develop cost-effective diagnostic tests to distinguish acute and chronic hepatits cases has created an opportunity among market participants. This research service analyses the Hepatitis B and C diagnostics markets in Europe, particularly, Hepatitis B NAT diagnostics, Hepatitis B Immunodiagnostics, Hepatitis C NAT diagnostics and ...